Clinical Trial Update: Efficacy and Safety of C2L-OCT-01 PR in Acromegalic Patients [Phase 3]

View source ↗

Summary

Phase 3 trial update on the efficacy and safety of C2L-OCT-01 PR in acromegaly patients; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acromegaly

Drugs mentioned

• C2L-OCT-01 PR

Snippet

Sponsor: Ambrilia Biopharma, Inc. | Conditions: Acromegaly | Phase 3 | Status: COMPLETED